Corporate Information

• Kancera meets the primary objectives of the KAND145 clinical phase I study

  3 May 2024

• Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study

  23 February 2024

• Kancera presents the statistical analysis of top line data from the FRACTAL study

  6 February 2024

• Kancera reports positive top line results from the FRACTAL study

  20 December 2023

• Kancera provides operational update in connection with release of financial interim report for third quarter 2023

  17 November 2023

• Kancera reports that the phase I study of KAND145 has received regulatory approval

  23 October 2023

• Kancera announces that the FRACTAL top line results are expected to be presented by the end of December 2023

  13 October 2023

• Kancera appoints new Chief Medical Officer

  1 September 2023

• Kancera provides operational update in connection with release of financial interim report for second quarter

  18 August 2023

• Newly published research publication confirms the potential for Kancera’s fractalkine blocker KAND567 in cardiovascular disease

  24 July 2023